R. Dorow

1.5k total citations
34 papers, 647 citations indexed

About

R. Dorow is a scholar working on Cellular and Molecular Neuroscience, Cognitive Neuroscience and Organic Chemistry. According to data from OpenAlex, R. Dorow has authored 34 papers receiving a total of 647 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cellular and Molecular Neuroscience, 9 papers in Cognitive Neuroscience and 8 papers in Organic Chemistry. Recurrent topics in R. Dorow's work include Neuroscience and Neuropharmacology Research (15 papers), Epilepsy research and treatment (7 papers) and Synthesis and pharmacology of benzodiazepine derivatives (5 papers). R. Dorow is often cited by papers focused on Neuroscience and Neuropharmacology Research (15 papers), Epilepsy research and treatment (7 papers) and Synthesis and pharmacology of benzodiazepine derivatives (5 papers). R. Dorow collaborates with scholars based in Germany, Italy and United Kingdom. R. Dorow's co-authors include Theodora Duka, H. Wachtel, R. Horowski, W. Kŕause, Th. Duka, A. Doenicke, David Stephens, Manfred Ackenheil, Heinz H. Pertz and J. D. Parkes and has published in prestigious journals such as Nature, The Journal of Clinical Endocrinology & Metabolism and Life Sciences.

In The Last Decade

R. Dorow

32 papers receiving 567 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Dorow Germany	14	300	184	147	104	82	34	647
A. Oblin France	8	260 0.9×	97 0.5×	197 1.3×	43 0.4×	22 0.3×	18	592
H.L. Wen China	14	245 0.8×	171 0.9×	131 0.9×	69 0.7×	20 0.2×	29	738
Gudrun Paalzow Sweden	16	404 1.3×	56 0.3×	251 1.7×	76 0.7×	13 0.2×	26	735
Rajesh C. Shrotriya United States	12	218 0.7×	103 0.6×	102 0.7×	33 0.3×	11 0.1×	16	560
M. Corsi Italy	13	627 2.1×	89 0.5×	471 3.2×	29 0.3×	33 0.4×	18	893
DennisL Murphy United States	10	140 0.5×	38 0.2×	59 0.4×	87 0.8×	36 0.4×	12	474
Wolfgang Meder Germany	9	360 1.2×	75 0.4×	295 2.0×	120 1.2×	15 0.2×	9	828
Martha Greiner United States	9	339 1.1×	78 0.4×	139 0.9×	33 0.3×	20 0.2×	10	865
C. Albano Italy	14	304 1.0×	80 0.4×	102 0.7×	146 1.4×	27 0.3×	36	743
Adam Kesingland United Kingdom	7	421 1.4×	69 0.4×	236 1.6×	75 0.7×	14 0.2×	7	870

Countries citing papers authored by R. Dorow

Since Specialization

Citations

This map shows the geographic impact of R. Dorow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Dorow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Dorow more than expected).

Fields of papers citing papers by R. Dorow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Dorow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Dorow. The network helps show where R. Dorow may publish in the future.

Co-authorship network of co-authors of R. Dorow

This figure shows the co-authorship network connecting the top 25 collaborators of R. Dorow. A scholar is included among the top collaborators of R. Dorow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Dorow. R. Dorow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dorow, R., et al.. (2006). Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties. Clinical Neuropharmacology. 29(2). 80–86. 77 indexed citations

Duka, Th., et al.. (1993). Abecarnil: A New ß-Carboline Anxiolytic Preliminary Clinical Pharmacology. PubMed. 11. 132–147. 3 indexed citations

Kŕause, W. & R. Dorow. (1993). Pharmacokinetics of two partial benzodiazepine receptor agonistic beta-carboline derivatives in healthy volunteers.. PubMed. 43(5). 511–5. 1 indexed citations

Duka, Theodora, et al.. (1992). Scopolamine-induced amnesia in humans: lack of effects of the benzodiazepine receptor antagonist β-carboline ZK 93426. Journal of Psychopharmacology. 6(3). 382–388. 6 indexed citations

Kŕause, W., et al.. (1990). Pharmacokinetics and endocrine effects of terguride in healthy subjects. European Journal of Clinical Pharmacology. 38(6). 609–615. 6 indexed citations

Dorow, R., et al.. (1988). Benzodiazepine Receptor Ligands: Tools for Memory Research in Clinical Pharmacology. PubMed. 6. 261–274. 1 indexed citations

Duka, Theodora, et al.. (1988). Human studies on the benzodiazepine receptor antagonist ?-carboline ZK 93 426: antagonism of lormetazepam's psychotropic effects. Psychopharmacology. 95(4). 463–71. 16 indexed citations

Duka, Theodora, et al.. (1988). β-Carbolines as Tools in Memory Research: Human Data with the β-Carboline ZK 93426. PubMed. 6. 246–260. 17 indexed citations

Dorow, R., et al.. (1987). Amnestic effects of lormetazepam and their reversal by the benzodiazepine antagonist Ro 15-1788. Psychopharmacology. 93(4). 507–14. 32 indexed citations

10.

Dorow, R., et al.. (1987). Clinical perspectives of β-carbolines from first studies in humans. Brain Research Bulletin. 19(3). 319–326. 15 indexed citations

11.

Duka, Theodora, David Stephens, W. Kŕause, & R. Dorow. (1987). Human studies on the benzodiazepine receptor antagonist ?-carboline ZK 93 426: preliminary observations on psychotropic activity. Psychopharmacology. 93(4). 421–7. 55 indexed citations

12.

Dorow, R.. (1987). FG 7142 and its anxiety-inducing effects in humans.. PubMed. 23(6). 781–2. 24 indexed citations

13.

Luquín, M. R., et al.. (1987). Parenteral administration of lisuride in Parkinson's disease.. PubMed. 45. 561–8. 8 indexed citations

14.

Dorow, R. & Theodora Duka. (1986). Anxiety: its generation by drugs and by their withdrawal.. PubMed. 41. 211–25. 13 indexed citations

15.

Gräf, Klaus-Jürgen, David Köhler, R. Horowski, & R. Dorow. (1986). Rapid regression of macroprolactinomas by the new dopamine partial agonist terguride. European Journal of Endocrinology. 111(4). 460–466. 5 indexed citations

16.

Klotz, Ulrich, Th. Duka, R. Dorow, & A. Doenicke. (1985). Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15‐1788.. British Journal of Clinical Pharmacology. 19(1). 95–98. 28 indexed citations

17.

Burns, Richard S., G Gopinathan, M. Hümpel, R. Dorow, & Donald B. Calne. (1984). Disposition of oral lisuride in parkinson's disease. Clinical Pharmacology & Therapeutics. 35(4). 548–556. 9 indexed citations

18.

Horowski, R. & R. Dorow. (1982). [Significance of pharmacokinetic findings for the clinical effect of benzodiazepines].. PubMed. 23(11). 632–40. 3 indexed citations

19.

Horowski, R. & R. Dorow. (1981). Influence of Estradiol and Other Gonadal Steroids on Central Effects of Lisuride and Comparable Ergot Derivatives. PubMed. Suppl 3. 169–181. 2 indexed citations

20.

Schachter, M, P.J. Bédard, A G Debono, et al.. (1980). The role of D-1 and D-2 receptors. Nature. 286(5769). 157–159. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact